Evidence map›Paper›PMID 39519692›Full record

ArticleMolecules (Basel, Switzerland)2024

Identification of a New Promising BAG3 Modulator Featuring the Imidazopyridine Scaffold.

Dafne Ruggiero, Emis Ingenito, Eleonora Boccia, Vincenzo Vestuto, Maria Rosaria Miranda, Stefania Terracciano, Gianluigi Lauro, Giuseppe Bifulco, Ines Bruno

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dafne RuggieroDepartment of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy.ORCID 0000-0001-9610-555X
Emis IngenitoDepartment of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy.ORCID 0009-0008-0798-503X
Eleonora BocciaDepartment of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy.ORCID 0009-0008-6202-547X
Vincenzo VestutoDepartment of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy.ORCID 0000-0002-3603-5526
Maria Rosaria MirandaDepartment of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy.ORCID 0009-0005-8296-1888
Stefania TerraccianoDepartment of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy.ORCID 0000-0001-5750-4929
Gianluigi LauroDepartment of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy.ORCID 0000-0001-5065-9717
Giuseppe BifulcoDepartment of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy.ORCID 0000-0002-1788-5170
Ines BrunoDepartment of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy.ORCID 0000-0002-1889-0115

Funding

PRIN2022-PNRR project "P2022CKMPW, TACSI Driver: a multitasks platform to guide the Target identification, As-sessment of the binding, Collection of natural products from waste, Synthesis of derivatives, and In vitro/In vivo polypharmacological profile evaluation of bioactive
6 · The paper itself

Abstract

The antiapoptotic BAG3 protein plays a crucial role in cellular proteostasis and it is involved in several signalling pathways governing cell proliferation and survival. Owing to its multimodular structure, it possesses an extensive interactome including the molecular chaperone HSP70 and other specific cellular partners, which make it an eminent factor in several pathologies, particularly in cancer. Despite its potential as a therapeutic target, very few BAG3 modulators have been disclosed so far. Here we describe the identification of a promising BAG3 modulator able to bind the BAG domain of the protein featuring an imidazopyridine scaffold and obtained through the application of the Groebke-Blackburn-Bienaymé chemical synthesis procedure. The disclosed compound

Indexed as

Adaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsImidazolesPyridinesAntineoplastic AgentsApoptosisCaspase 3Cell Line, TumorCell ProliferationHumansProtein BindingAdaptor Proteins, Signal TransducingAntineoplastic AgentsApoptosis Regulatory ProteinsBAG3 protein, humanCaspase 3ImidazolesimidazopyridinePyridinesBAG3 proteinBAG domain modulatorGroebke–Blackburn–Bienaymé reactionimidazopyridine scaffoldSurface Plasmon Resonance assay

Identifiers

PMID39519692
PMCPMC11547576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.